Abstract
The immunological milieu of premalignant lesions of the uterine cervix has not been sufficiently explored. The rationale for immunological approaches for the treatment of the premalignant lesions is as to prevent secondary premalignant lesions and their progression to cancer. Among the challenges of immunotherapeutic approaches for cancer are the multitudes of mechanisms by which cancers are known to subvert the immune defenses. Human papillomavirus (HPV) is known as a cause of uterine cervical cancer and cervical intraepithelial neoplasia (CIN). HPVs related to cancer express two main oncogenes, i.e., E6 and E7, considered as tumorigenic genes; their integration into the host genome results in the abnormal regulation of cell cycle control. Due to their molecular characteristics, these oncogenes represent a target for immunotherapy. The development of HPV-associated cancers depends on efficient negative regulation of cell cycle control that supports the accumulation of genetic damage and immune evasion that enables the virus to go undetected for a long time. Noting that HPV-related lesions and tumors usually present MHC class I down-regulation, impaired antigen-processing ability, avoidance of T-cell mediated killing, increased immunosuppression due to Treg infiltration and secrete immunosuppressive cytokines. This chapter focuses on the immunological aspects of premalignant lesions of the uterine cervix and highlights strategies for immunotherapy and several promising immunotherapy technologies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.